Indications for: VELETRI
Pulmonary arterial hypertension (PAH; WHO Group I) in patients with NYHA Class III or IV symptoms, to improve exercise ability.
Give by continuous chronic IV infusion through a central venous catheter. Initially 2ng/kg/min; increase in increments of 1–2ng/kg/min at ≥15min intervals based on response. Decrease dose gradually in 2ng/kg/min decrements at ≥15min intervals until dose-limiting effects resolve.
Heart failure due to severe left ventricular systolic dysfunction. Pulmonary edema.
Avoid abrupt withdrawal or large dose reductions (may cause rebound pulmonary hypertension). Risk of pulmonary embolism or systemic embolism; give anticoagulant therapy unless contraindicated. Monitor BP and heart rate during initiation and after dose changes. Pregnancy. Nursing mothers.
Hypotensive effects may be potentiated by diuretics, antihypertensive agents, other vasodilators. Increased risk of bleeding with anticoagulants, antiplatelets. May potentiate digoxin concentration; monitor for digoxin toxicity.
Nausea, vomiting, headache, hypotension, flushing, chest pain, dizziness, bradycardia, dyspnea, abdominal pain, musculoskeletal pain, tachycardia, jaw pain, diarrhea, flu-like symptoms, anxiety/nervousness.
Generic Drug Availability: